Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

OrbusNeich Completes Enrollment of China Stent Trial

publication date: Oct 12, 2010
OrbusNeich has completed patient enrollment in a 180-patient trial of its Genous Bio-engineered R stent at 11 sites in China. OrbusNeich positions the Genous stent as an alternative to drug-eluting stents for patients who either do not respond to or cannot tolerate long-term dual antiplatelet therapy. Many of these patients have diabetes. The Genous sten has been available around the world since 2005. More details....


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital